| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 18.18 | 4.8% |
| Total Income | 18.61 | 5.4% |
| Expenditure | 15.96 | 5.3% |
| PBT | 2.65 | 5.8% |
| Net Profit | 2.19 | 15.2% |
| OPM | 14.36% | 3.73pp |
| NPM | 11.75% | 1.00pp |
| EPS | 1.84 | 13.6% |
Sanjivani Paranteral Ltd Reports 41.3% YoY Revenue Growth in Q4 FY25
28 May 2025 · 28 May 2025, 02:09 am
Summary
Sanjivani Paranteral Ltd, a Mumbai-based pharmaceutical company, has reported its financial results for the quarter and year ended 31 March 2025. The company's revenue from operations grew by 41.3% YoY to INR 181.8 mn in Q4 FY25. The EBITDA margin stood at 16.8%, down 42bps YoY. The Profit After Tax (PAT) stood at INR 21.9 mn, up 74.4% YoY. The company's total income for FY25 was INR 713.1 mn, a 30.1% YoY increase.
Key Highlights
- 1
Revenue from operations grew 41.3% YoY to INR 181.8 mn in Q4 FY25
- 2
EBITDA margin stood at 16.8% in Q4 FY25
- 3
Profit After Tax (PAT) stood at INR 21.9 mn, up 74.4% YoY
- 4
Total income for FY25 was INR 713.1 mn, a 30.1% YoY increase
- 5
Injectables segment contributed INR 130.8 mn to the total revenue, up 16.1% YoY
Management Comments
Mr. Ashwani Khemka
We are pleased with the performance this quarter, which reflects our continued focus on operational efficiency, quality manufacturing, and strategic market expansion. Our efforts to strengthen the core business and explore growth opportunities have yielded encouraging results. As we move forward, we remain committed to innovation, regulatory compliance, and delivering value to our stakeholders.
Informational and educational content only. Not investment advice.